FAQ/Help |
Calendar |
Search |
Today's Posts |
|
Thoracic Outlet Syndrome Thoracic Outlet Syndrome/Brachial Plexopathy. In Memory Of DeAnne Marie. |
|
Thread Tools | Display Modes |
06-24-2007, 02:23 PM | #1 | |||
|
||||
Member
|
HomeSearchListingsResourcesHelpWhat's NewAbout Treatment of Thoracic Outlet Syndrome (TOS) With Botox This study is not yet open for patient recruitment. Verified by University of British Columbia March 2007 Sponsors and Collaborators: University of British ColumbiaAllergan Information provided by: University of British Columbia ClinicalTrials.gov Identifier: NCT00444886 Purpose The purpose of this study is:
Drug: Botulinum Toxin Type A injection (BOTOX) Phase II MedlinePlus related topics: Thoracic Outlet Syndrome Study Type: Interventional Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study Official Title: Treatment of Thoracic Outlet Syndrome With Botulinum Toxin Injection: A Double-Blind, Randomized Controlled Trial Further study details as provided by University of British Columbia: Primary Outcome Measures:
Study start: May 2007; Expected completion: May 2009 Background: Thoracic Outlet Syndrome (TOS) is a symptom complex consisting of pain, paresthesias and often functional impairment caused by compression of the neurovascular supply to the upper limb. Impingement may occur at the interscalene triangle, and both anesthetic blockade and chemodenervation of the scalene muscles have been shown to temporarily improve symptoms of TOS in non-randomized controlled trials. Objective: To assess the effect of Botulinum Toxin Type A (BTX-A) injections into the scalene muscles on pain, paresthesias and function in subjects with TOS. Hypothesis: BTX-A injected into the anterior and middle scalene muscles will reduce the irritation on the neurovascular structures at the interscalene triangle in subjects with TOS. This will lead to reductions in pain and paresthesias, and improvements in function when compared with injection of placebo. Intervention: Each subject will receive an injection under EMG guidance into the anterior and middle scalene muscles of either 75 units of BTX-A (experimental group), or normal saline (control group). Both groups will be provided with a stretching and strengthening exercise program. Eligibility Ages Eligible for Study: 19 Years and above, Genders Eligible for Study: Both Criteria Inclusion Criteria:
Please refer to this study by ClinicalTrials.gov identifier NCT00444886 Heather Finlayson, MD, FRCPC 604-714-4112 heather.finlayson@vch.ca Canada, British Columbia GF Strong Rehabilitation Centre, Vancouver, British Columbia, V5Z 2G9, Canada Heather Finlayson, MD, FRCPC 604-714-4112 Russell O'Connor, MD, Sub-Investigator Heather Finlayson, MD, FRCPC, Sub-Investigator Study chairs or principal investigators Andrew Travlos, MD, Principal Investigator, University of British Columbia More Information Study ID Numbers: H06-03355 Last Updated: March 7, 2007 Record first received: March 7, 2007 ClinicalTrials.gov Identifier: NCT00444886 Health Authority: Canada: Health Canada ClinicalTrials.gov processed this record on June 21, 2007 U.S. National Library of Medicine, Contact NLM Customer Service National Institutes of Health, Department of Health & Human Services, USA.gov Copyright, Privacy, Accessibility, Freedom of Information Act |
|||
Reply With Quote |
|
|
Similar Threads | ||||
Thread | Forum | |||
Looking at clinical trials | Parkinson's Disease Clinical Trials | |||
Clinical trials - what do you think? | Parkinson's Disease | |||
Clinical Trials | Reflex Sympathetic Dystrophy (RSD and CRPS) | |||
Clinical Trials | Reflex Sympathetic Dystrophy (RSD and CRPS) | |||
Worthless clinical trials | ALS |